Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Caglevic C, et al. Among authors: listi a. Ther Adv Respir Dis. 2015 Aug;9(4):164-72. doi: 10.1177/1753465815579608. Epub 2015 Apr 7. Ther Adv Respir Dis. 2015. PMID: 25855060 Free article. Review.
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listì A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V. Fanale D, et al. Among authors: listi a. Anal Cell Pathol (Amst). 2015;2015:690916. doi: 10.1155/2015/690916. Epub 2015 Sep 21. Anal Cell Pathol (Amst). 2015. PMID: 26484003 Free PMC article. Review.
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. Passiglia F, et al. Among authors: listi a. Expert Opin Investig Drugs. 2016;25(4):385-92. doi: 10.1517/13543784.2016.1152261. Epub 2016 Feb 24. Expert Opin Investig Drugs. 2016. PMID: 26881293 Review.
Nintedanib in NSCLC: evidence to date and place in therapy.
Bronte G, Passiglia F, Galvano A, Barraco N, Listì A, Castiglia M, Rizzo S, Fiorentino E, Bazan V, Russo A. Bronte G, et al. Among authors: listi a. Ther Adv Med Oncol. 2016 May;8(3):188-97. doi: 10.1177/1758834016630976. Epub 2016 Feb 16. Ther Adv Med Oncol. 2016. PMID: 27239237 Free PMC article. Review.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Incorvaia L, et al. Among authors: listi a. Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20. Adv Ther. 2019. PMID: 31432460 Free PMC article. Review.
43 results